You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at ....

CASE ALLEGATIONS: Baxter, through its subsidiaries, provides a portfolio of healthcare products.

The Baxter class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Baxter's Novum IQ Large Volume Pump (“Novum LVP”) suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (ii) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (iii) Baxter's attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; and (iv) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps.

The Baxter class action lawsuit further alleges that on July 31, 2025, Baxter announced that it had decided to“voluntarily and temporarily pause shipments and planned installations of the Novum LVP” and that it was“unable to currently commit to an exact timing for resuming shipment and installation for Novum IQ LVPs.” Defendants further stated that they had offered“customers the option of our Spectrum infusion pump as an alternative” and that Baxter's low-end guidance assumes that Baxter does not resume shipments for Novum LVPs before the end of the year, according to the complaint. The Baxter class action lawsuit alleges that on this news, the price of Baxter common stock fell more than 22%.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Baxter common stock during the Class Period to seek appointment as lead plaintiff in the Baxter class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Baxter class action lawsuit. The lead plaintiff can select a firm of its choice to litigate the Baxter class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Baxter class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five firms combined, according to ISS. With 200 attorneys in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.

Contact:
Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
...